This observation, together with clinical evidences that up to 30% of IBD patients do not respond to anti-TNF-α therapies [65,66,67], underlines the urgent need to identify more promising probiotic strains which could be able to interfere with the TNF-α pathway even in IBD patients. This evidence concerns the gene TNF and inflammatory bowel disease.